JPMorgan analyst Lisa Gill raised the firm’s price target on Progyny (PGNY) to $26 from $25 and keeps a Neutral rating on the shares. The company reported a good Q3 and has positive selling season trends heading into fiscal 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY: